Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better ...

UB researchers have published the first longitudinal studies of paramagnetic rim lesions, an indicator of brain inflammation in MS.

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ...

The main external factors causing drug resistance are tumor immune microenvironment components, such as myelosuppressive cell (MDSC), regulatory T cell (Treg), M2 macrophages, and immunosuppressive ...

Autoimmune diseases affect millions of people worldwide, often in ways that can be life-altering. These conditions occur when ...

Immune checkpoint inhibitors may heighten cardiovascular risks by altering immune interactions in atherosclerotic plaques, ...

Synthetic biology techniques have emerged as transformative tools in the tug-of-war between humans and drug-resistant ...

and disease-modifying antirheumatic drugs (DMARDs) like methotrexate. They can help reduce inflammation and related symptoms. If these medications fail to improve symptoms, biologic medications are ...

1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with a statistically significant higher risk of cancer incidence ...